Gastroenterologist perceptions of faecal microbiota transplantation

作     者：Sudarshan Paramsothy Alissa J Walsh Thomas Borody Douglas Samuel Johan van den Bogaerde Rupert WL Leong Susan Connor Watson Ng Hazel M Mitchell Nadeem O Kaakoush Michael A Kamm 

作者机构：Gastroenterology and Hepatology DepartmentSt Vincent’s Hospital Centre for Digestive Diseases Gastroenterology and Hepatology DepartmentBankstown-Lidcombe Hospital Gastroenterology and Hepatology DepartmentNambour General Hospital Gastroenterology and Hepatology DepartmentLiverpool Hospital University of New South WalesSchool of Biotechnology and Biomolecular Sciences Departments of Gastroenterology and MedicineSt Vincent's Hospital and University of Melbourne 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2015年第21卷第38期

页      面：10907-10914页

核心收录：

学科分类：1002[医学-临床医学] 10[医学] 

基　　金：Supported by The Clinical trial(Clinical Trials.gov Identifier:NCT01896635)this study was performed in conjunction with has received funding from the Broad Medical Research Program at CCFA the GESA IBD Clinical Research Grant 

主　　题：Perceptions Gastroenterologist Clostridium diffici 

摘      要：AIM: To explore gastroenterologist perceptions towards and experience with faecal microbiota transplantation(FMT).METHODS: A questionnaire survey consisting of 17 questions was created to assess gastroenterologists attitude towards and experience with FMT. This was anonymously distributed in hard copy format amongst attendees at gastroenterology meetings in Australia between October 2013 and April 2014. Basic descriptive statistical analyses were performed.RESULTS: Fifty-two clinicians participated. Twenty one percent had previously referred patients for FMT,8% more than once. Ninety percent would refer patients with Clostridium difficile infection(CDI) for FMT if easily available,37% for ulcerative colitis,13% for Crohn s disease and 6% for irritable bowel syndrome. Six percent would not refer any indication,including recurrent CDI. Eighty-six percent would enroll patients in FMT clinical trials. Thirty-seven percent considered the optimal mode of FMT administration transcolonoscopic,17% nasoduodenal,13% enema and 8% oral capsule. The greatest concerns regarding FMT were: 42% lack of evidence,12% infection risk,10% non infectious adverse effects/lack of safety data,10% aesthetic,10% lack of efficacy,4% disease exacerbation,and 2% inappropriate use; 6% had no concerns. Seventy seven percent believed there is a lack of accessibility while 52% had an interest in learning how to provide FMT. Only 6% offered FMT at their institution.CONCLUSION: Despite general enthusiasm,most gastroenterologists have limited experience with,or access to,FMT. The greatest concerns were lack of supportive evidence and safety issues. However a significant proportion would refer indications other than CDI for FMT despite insufficient evidence. These data provide guidance on where education and training are required.